Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.50 |
| ▸ | QDPR | P09417 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30454060 | 1.00 | HTR2C (0.51) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL171110 | 0.81 | SIGMAR1 (0.49) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL14761633 | 0.81 | CDK9 (0.57) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL13490658 | 0.81 | SIGMAR1 (0.49) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL3453255 | 0.81 | HTR2C (0.51) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL171596 | 0.81 | PIM1 (0.51) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL7940586 | 0.81 | SIGMAR1 (0.49) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL31651838 | 0.81 | SIGMAR1 (0.45) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL16434801 | 0.81 | SIGMAR1 (0.45) | HTR2CSIGMAR1QDPRPIM1PIM3 | |
| SCHEMBL169395 | 0.80 | SIGMAR1 (0.66) | HTR2CSIGMAR1QDPRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12365670-B2 | GLP-IR agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2025-07-22 | — | — | US | disclosed |
| CN-113227068-B | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2022-01-27 | — | — | US | disclosed |
| CN-113227068-A | GLP-1R agonists and uses thereof | 上海齐鲁锐格医药研发有限公司 | 2021-08-06 | — | — | CN | disclosed |
| US-10844049-B2 | GLP-1R agonists and uses thereof | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-24 | — | — | US | disclosed |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | QILU REGOR THERAPEUTICS INC. (CN) | 2020-09-10 | — | — | US | disclosed |
| US-7196104-B2 | Thiazolyl urea compounds and methods of uses | AMGEN, INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2004-02-26 | — | — | US | disclosed |
| US-6645990-B2 | For prophylaxis and therapy of diseases, such as cell proliferation or apoptosis mediated diseases | AMGEN INC. | 2003-11-11 | — | — | US | disclosed |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | AMGEN INC. | 2002-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035362-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, IAPP | HTR2C 1375/4885SIGMAR1 562/4885QDPR 4371/4885 |
| US-20020193405-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HTR2C 4799/4885SIGMAR1 2218/4885QDPR 2050/4885 |
| US-10844049-B2 | GLP-1R agonists and uses thereof | GLP1R, GPR119, GIPR | HTR2C 558/4885SIGMAR1 380/4885QDPR 2666/4885 |
| US-12365670-B2 | GLP-IR agonists and uses thereof | GLP1R, GPR119, GIPR | HTR2C 815/4885SIGMAR1 765/4885QDPR 2965/4885 |
| US-20200283424-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | HTR2C 558/4885SIGMAR1 380/4885QDPR 2666/4885 |
| US-20220024901-A1 | GLP-1R AGONISTS AND USES THEREOF | GLP1R, GPR119, GIPR | HTR2C 644/4885SIGMAR1 442/4885QDPR 2871/4885 |
| US-20040039029-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HTR2C 4799/4885SIGMAR1 2218/4885QDPR 2050/4885 |
| US-20040044044-A1 | Thiazolyl urea compounds and methods of uses | SLC14A1, UMPS, BAX | HTR2C 4799/4885SIGMAR1 2218/4885QDPR 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.